BioCentury | Jan 7, 2020
Finance

BioIntervene takes on adenosine in pain, raises $30M

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic. The company plans to...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Jun 20, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus aureus infection. Screening of a CRISPR single-guide RNA (sgRNA) library in a human lung lymphoblast cell line expressing CRISPR-associated...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cardiovascular; neurology

INDICATION: Atherosclerosis; stroke Mouse studies suggest inhibiting adenosine kinase could help treat atherosclerosis and stroke. In a mouse model of atherosclerosis, vascular endothelial cell-specific knockout of adenosine kinase decreased atherosclerotic lesion size and the necrotic...
BC Innovations | May 31, 2017
Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma; multiple myeloma (MM) Patient sample, cell culture and mouse studies identified a nucleoside analog that could help treat primary effusion lymphoma (PEL) and MM. High throughput screening of a small molecule...
BC Innovations | Apr 17, 2014
Cover Story

Contaminating cancer genomes

Two European teams have pinpointed the DNA-protective enzyme 7,8-dihydro-8-oxoguanine triphosphatase as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. 1,2 Both groups have identified collections of small molecule inhibitors of...
BioCentury | Jul 30, 2012
Tools & Techniques

Screening beta

In the last 16 months Evotec AG has done two deals using its porcine beta cell screening technology. The first was a collaboration with Harvard University to discover diabetes therapies targeting beta cell regeneration. This...
BC Innovations | Jun 14, 2012
Targets & Mechanisms

Beta testing adenosine receptor agonists

Researchers at the University of California, San Francisco have used a zebrafish screen to identify an adenosine receptor agonist that improved both b cell regeneration and glucose control in diabetic mice. 1 The discovery could...
BC Innovations | Mar 22, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Adenosine kinase Cell culture and rodent studies identified adenosine kinase inhibitors that could help treat diabetes. An in vitro small molecule screen identified...
BC Week In Review | Mar 2, 1998
Clinical News

Metabasis regulatory update

Metabasis received notice of allowance for a U.S. patent covering a series of adenosine kinase inhibitors and their use to treat inflammation, pain and neurological diseases. Metabasis is a majority-owned subsidiary of Gensia Sicor Inc....
Items per page:
1 - 10 of 11